Received May 11, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Developed shingles; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis. In JAN-2026, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced shingles (Verbatim: Developed shingles). The outcome of the shingles was resolved (duration 1 month). It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK receipt date: 24-APR-2026 The patient was called regarding his second dose of Shingrix stating he received his first dose toward the end of JAN-2026 (sometime between JAN 23-26) and developed shingles for about a month. He was now due for his second dose and has questions and concerns regarding developing shingles again. The batch number was not provided, and unable to contact the reporter.